Urologic malignancies in kidney transplantation
| Autor: | Laura Hickman, Thomas J. Guzzo, Deirdre Sawinski, Jayme E. Locke |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Urologic Neoplasms
medicine.medical_specialty medicine.medical_treatment Population 030232 urology & nephrology 030230 surgery 03 medical and health sciences 0302 clinical medicine Risk Factors Renal cell carcinoma Cancer screening medicine Animals Humans Immunology and Allergy Pharmacology (medical) Intensive care medicine education Kidney transplantation Transplantation education.field_of_study business.industry Incidence (epidemiology) Immunosuppression medicine.disease Kidney Transplantation Optimal management surgical procedures operative business |
| Zdroj: | American Journal of Transplantation. 18:13-22 |
| ISSN: | 1600-6135 |
| DOI: | 10.1111/ajt.14533 |
| Popis: | With advances in immunosuppression, graft and patient outcomes after kidney transplantation have improved considerably. As a result, long-term complications of transplantation, such as urologic malignancies, have become increasingly important. Kidney transplant recipients, for example, have a 7-fold risk of renal cell carcinoma (RCC) and 3-fold risk of urothelial carcinoma (UC) compared with the general population. While extrapolation of data from the general population suggest that routine cancer screening in transplant recipients would allow for earlier diagnosis and management of these potentially lethal malignancies, currently there is no consensus for posttransplantation RCC or UC screening as supporting data are limited. Further understanding of risk factors, presentation, optimal management of, and screening for urologic malignancies in kidney transplant patients is warranted, and as such, this review will focus on the incidence, surveillance, and treatment of urologic malignancies in kidney transplant recipients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text